GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Earnings per Share (Diluted)

T2 Biosystems (T2 Biosystems) Earnings per Share (Diluted) : $-146.00 (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Earnings per Share (Diluted)?

T2 Biosystems's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-2.55. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-146.00.

T2 Biosystems's EPS (Basic) for the three months ended in Dec. 2023 was $-2.55. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-146.00.

T2 Biosystems's EPS without NRI for the three months ended in Dec. 2023 was $-2.56. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-140.22.

During the past 3 years, the average EPS without NRIGrowth Rate was 78.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.60% per year.

During the past 12 years, T2 Biosystems's highest 3-Year average EPS without NRI Growth Rate was 78.20% per year. The lowest was -132.40% per year. And the median was 14.70% per year.


T2 Biosystems Earnings per Share (Diluted) Historical Data

The historical data trend for T2 Biosystems's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Earnings per Share (Diluted) Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -130.00 -1,950.00 -1,550.00 -1,222.14 -19.19

T2 Biosystems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -141.00 -132.00 -8.00 -3.45 -2.55

Competitive Comparison of T2 Biosystems's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, T2 Biosystems's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's PE Ratio distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's PE Ratio falls into.



T2 Biosystems Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

T2 Biosystems's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-50.077-0)/2.610
=-19.19

T2 Biosystems's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-10.34-0)/4.058
=-2.55

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-146.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


T2 Biosystems  (NAS:TTOO) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


T2 Biosystems Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems (T2 Biosystems) Business Description

Traded in Other Exchanges
N/A
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
Executives
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard director 101 HARTWELL AVENUE, LEXINGTON MA 02421